Advertisement

Picture Kentro Design Corporate and Web Design Berlin 600x60px
Document › Details

AGC Asahi Glass. (12/20/16). "Press Release: AGC Signs Agreement for Acquisition of a Leading Biopharmaceuticals CDMO, CMC Biologics". Tokyo.

Organisations Organisation CMC Biologics A/S
  Today AGC Biologics Copenhagen
  Group Asahi Glass (AGC) (Group)
  Organisation 2 Asahi Glass Co., Ltd. (AGC)
  Today Asahi Glass (AGC) (Group)
  Group Asahi Glass (AGC) (Group)
Products Product contract manufacturing (biologicals)
  Product 2 biopharmaceutical
Index term Index term CMC Biologics–Asahi Glass: investment, 201612– acquisition JPY60b of 100% of CMC Biologics by Asahi Glass
Person Person Mahler, Gustavo (CMC Biologics 201412 Global COO)
     


AGC Asahi Glass (“AGC”), a world-leading manufactuer of glass, chemicals and high-tech materials, announces that it has entered into an agreement to acquire 100% of the shares of CMC Biologics (“CMC”), a world-leading biologics Active Pharmaceutical Ingredients (“API”) manufactuer with major investors including Monitor Clipper Partners and European Equity Partners, for a purchase price of approximately 60 billion Japanese yen. The agreement remains subject to approval from the relevant antitrust authority, and the acquisition is expected to be completed in January 2017.

CMC is a Contract Development and Manufacturing Organization (“CDMO”), offering biological API manufacturing service with mammalian and microbial hosts. The company provides high value-added cell line construction, process development, scale-up and manufacturing of API used in drug development (pre-clinical and clinical trials) and in commercially marketed biopharmaceutical drugs. With approximately 530 employees, CMC operates on a global scale with production facilities in Denmark (Copenhagen) and USA (Seattle and Berkeley).

David Kauffmann, Chairman of CMC Biologics said “I am excited by CMC Biologics becoming part of AGC a world-class company committed to excellence and high customer satisfaction. AGC’s dedication to best technology solutions and long-time partnership with clients align so well with CMC Biologics’ quest to be the preferred biologics CDMO service partner for the world’s top pharmaceutical and biotech companies.”

“We are honored to become part of AGC, a successful global company with a long term business strategy and resources to be the ideal owner of CMC Biologics. The CMC management team look forward to becoming one team with AGC, to bring and combine broad, as well as focused innovative solutions to our clients” said Gustavo Mahler, President & Chief Executive Officer of CMC Biologics, and added “With this transaction, I am confident that our clients will receive even further benefits from our combined high level of expertise, years of experience and global offerings.”

AGC has been engaged in contract manufacturing business since the early 2000s. Its acquisition of CMC is part of AGC’s strategy to expand its biologics CDMO operations, complementing AGC’s current operations in Japan and Europe*(note). The business integration with CMC will enable AGC to offer world-leading biologics CDMO API services, with a host of best-in-class technologies and manufacturing solutions by both mammalian and microbial operations for its global customer base.

Under its management policy, AGC plus, the AGC Group has designated its Life Science Business as one of its strategic areas. Through the business integration, the AGC Group will accelerate and expand its biopharmaceutical contract services business around the world.


* AGC’s European operations made a full-fledged start through the acquisition of German CDMO Biomeva in August this year. Please refer to AGC’s press release at: http://www.agc.com/english/news/20160906e.pdf


..............................................



Profile of CMC Biologics

Company: CMC Biologics
Representative: Gustavo Mahler
Locations: Denmark (Copenhagen) and USA (Seattle and Berkeley)
Established: 2001
Business Description: A global contract process development and manufacturer of biopharmaceuticals


About the AGC Group

AGC Asahi Glass (or also called AGC, Registered Company name: Asahiu Glass Co., Ltd., Headquarters: Tokyo, President & CEO: Takuya Shimamura) is the parent company of the AGC Group, a world-leading glass solution provider and supplier of flat, automative and display glass, chemicals, ceramics and other high-tech materials and components. Based on more than a century of technical innovation, the AGC Group has developed a wide range of cutting-edge products. The AGC Group employs some 50,000 people worldwide and generates annual sales of approximately 1.3 trillion Japanese yen through business in about 30 countries. For more information please visit www.agc-group.com.




Junichi Kobayashi, General Manager, Corporate Communications & Investor Relations Office AGC Asahi Glass
(Contact: Tomoko Komazaki; Tel: +81-3-3218-5603; E-mail: info-pr@agc.com)

   
Record changed: 2019-06-09

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px

More documents for Asahi Glass (AGC) (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group BioPharm America 2019 Boston September 600x60px




» top